Skip to main content
AMGN
NASDAQ Life Sciences

Teva Wins FDA Approval for Biosimilar of Amgen's Xgeva

Tom Rudovsky · Reported by Seeking Alpha
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$418.13
Mkt Cap
$226.054B
52W Low
$269.77
52W High
$447.03
52W Position info
55% above low
Off High info
6.5% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

AMGN sits 55% above its 52-week low of $269.77.

Summary

Teva has received FDA approval for a biosimilar version of Amgen's Xgeva (denosumab), introducing direct competition for the bone-targeting agent. Xgeva is a significant product for Amgen, and biosimilar entry typically leads to price erosion and market share loss. This approval follows a series of challenges for Amgen, including the FDA's proposal to withdraw Tavneos and the recent cardiovascular setback for pelacarsen. Investors will watch for Teva's launch timing and pricing strategy, which will determine the near-term revenue impact on Amgen's franchise.

At the time of this announcement, AMGN was trading at $418.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $226.1B. The 52-week trading range was $269.77 to $447.03. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.


Price Chart

Share this article

Copied!

AMGN - Latest Insights

AMGN
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $477.40
Real-time Price: $447.59 info
Change: -$29.81 (-6%) info
Market Cap: $242.469B info
AMGN
Nov 03, 2026, 6:37 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $464.92
Real-time Price: $447.59 info
Change: -$17.33 (-4%) info
Market Cap: $242.469B info
AMGN
Nov 03, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $463.00
Real-time Price: $447.59 info
Change: -$15.41 (-3%) info
Market Cap: $242.469B info
AMGN
Nov 03, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $460.57
Real-time Price: $447.59 info
Change: -$12.98 (-3%) info
Market Cap: $242.469B info
AMGN
Oct 26, 2026, 9:23 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $448.79
Real-time Price: $447.59 info
Change: -$1.20 (-0.27%) info
Market Cap: $242.469B info